India Bans OTC Cough Syrup Sales, Requires Doctor Prescription

The move follows years of scrutiny on India's pharmaceutical export sector. Indian-made cough syrups were linked to child deaths in Gambia, Uzbekistan, and Cameroon between 2022 and 2023, triggering World Health Organization alerts and import bans from multiple countries. Those incidents involved diethylene glycol and ethylene glycol contamination, not the active ingredients themselves. They exposed gaps in India's drug quality control and distribution oversight.

India's drug regulator, the Central Drugs Standard Control Organization, has since tightened manufacturing standards and increased inspections. The prescription mandate for syrups is the latest step in that sequence. It shifts the burden of screening from the pharmacist to the prescribing doctor, who must evaluate whether the syrup is appropriate for the patient's condition.

The amendment also affects the domestic pharmaceutical industry. Syrup-based formulations are a significant revenue stream for Indian drugmakers, particularly in the pediatric and cough-cold segments. Companies that relied on OTC syrup sales will need to adjust distribution and marketing strategies. Prescription-only status typically reduces volume. It can improve pricing power and brand loyalty if the product is well-established with doctors.

The notification does not specify a transition period. Pharmacies holding existing stock of syrup formulations may sell them without a prescription until the stock is exhausted. New supplies will require prescription documentation. State drug controllers are expected to issue enforcement guidelines in the coming weeks.